EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of α-Synuclein

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Yang, Jee Eun ^a   Rhoo, Kun Yil ^a   Lee, Soonkoo ^a   Lee, Jong Tak ^a   Park, Jae Hyung ^a   Bhak, Ghibom ^a   Paik, Seung R ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; CATECHIN; EPIGALLOCATECHIN GALLATE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG EFFECT; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; CATECHIN; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MICROSCOPY, ELECTRON, TRANSMISSION; PARKINSON DISEASE;

EID: 85038809638     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-18349-z     Document Type: Article

References (28)

1. Goedert, M. a-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501 (2001)
2. Polymeropoulos, M. H. et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997)
3. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. &Goedert, M. a-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473 (1998)
4. Sacchettini, J. C. &Kelly, J. W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov. 1, 267-275 (2002)
5. Lashuel, H. A. et al. a-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102 (2002)
6. Volles, M. J. et al. Vesicle permeabilization by protofibrillar a-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819 (2001)
7. Fink, A. L. The aggregation and fibrillation of a-synuclein. Acc. Chem. Res. 39, 628-634 (2006)
8. Kaylor, J. et al. Characterization of oligomeric intermediates in a-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F a-synuclein. J. Mol. Biol. 353, 357-372 (2005)
9. Glaser, C. B., Yamin, G., Uversky, V. N. &Fink, A. L. Methionine oxidation, a-synuclein and Parkinson's disease. Biochim. Biophys. Acta. 1703, 157-169 (2005)
10. Yamin, G., Uversky, V. N. &Fink, A. L. Nitration inhibits fibrillation of human a-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542, 147-152 (2003)
11. Li, J., Zhu, M., Rajamani, S., Uversky, V. N. &Fink, A. L. Rifampicin inhibits a-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11, 1513-1521 (2004)
12. Zhu, M. et al. The flavonoid baicalein inhibits fibrillation of a-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 26846-26857 (2004)
13. Lee, J. H. et al. Radiating amyloid fibril formation on the surface of lipid membranes through unit-assembly of oligomeric species of a-synuclein. PLoS One 7, e47580, https://doi.org/10.1371/journal.pone.0047580 (2012)
14. Bhak, G. et al. Molecular inscription of environmental information into protein suprastructures: temperature effects on unit assembly of a-synuclein oligomers into polymorphic amyloid fibrils. Biochem. J. 464, 259-269 (2014)
15. Bhak, G., Lee, J. H., Hahn, J. S. &Paik, S. R. Granular assembly of a-synuclein leading to the accelerated amyloid fibril formation with shear stress. PLoS One 4, e4177, https://doi.org/10.1371/journal.pone.0004177 (2009)
16. Lee, D. et al. Photoconductivity of pea-pod-type chains of gold nanoparticles encapsulated within dielectric amyloid protein nanofibrils of a-synuclein. Angew. Chem. Int. Ed. 50, 1332-1337 (2011)
17. Lee, J. H., Bhak, G., Lee, S. G. &Paik, S. R. Instantaneous amyloid fibril formation of a-synuclein from the oligomeric granular structures in the presence of hexane. Biophys. J. 95, L16-18 (2008)
18. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566 (2008)
19. Singh, B. N., Shankar, S. &Srivastava, R. K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 82, 1807-1821 (2011)
20. Ortega-Arellano, H. F., Jimenez-Rio, M. &Velez-Pardo, C. Life span and locomotor activity modification by glucose and polyphenols in Drosophila melanogaster chronically exposed to oxidative stress-stimuli: implications in Parkinson's disease. Neurochem. Res. 36, 1073-1086 (2011)
21. Bieschke, J. et al. EGCG remodels mature A-synuclein and amyloid-B fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. USA 107, 7710-7715 (2010)
22. Hudson, S. A., Ecroyd, H., Kee, T. W. &Carver, J. A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J. 276, 5960-5972 (2009)
23. Lorenzen, N. et al. How epigallocatechin gallate can inhibit A-synuclein oligomer toxicity in vitro. J. Biol. Chem. 289, 21299-21310 (2014)
24. Konijnenberg, A. et al. Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to a-synuclein. Anal Chem 88, 8468-8475 (2016)
25. Zhao, J. et al. Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of A-synuclein, and protects PC12 cells against A-synuclein-induced toxicity. RSC Adv. 7, 32508-32517 (2017)
26. Wantyghem, J., Baron, M. H., Picquart, M. &Lavialle, F. Conformational changes of Robinia pseudoacacia lectin related to modifications of the environment: FTIR investigation. Biochemistry 29, 6600-6609 (1990)
27. Bhak, G., Lee, S., Park, J. W., Cho, S. &Paik, S. R. Amyloid hydrogel derived from curly protein fibrils of a-synuclein. Biomaterials 31, 5986-5995 (2010)
28. Paik, S. R., Lee, J. H., Kim, D. H., Chang, C. S. &Kim, J. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Arch. Biochem. Biophys. 344, 325-334 (1997)